Immunotherapy News and Research

Latest Immunotherapy News and Research

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has established the University of California San Francisco (UCSF) as the second enrolling site for its Phase II Merkel cell carcinoma clinical trial (OMS-I110).

11 Jul 2012

Merck, PDS Biotechnology enter licensing agreement for Versamune

PDS Biotechnology Corporation announced today that they have entered into an exclusive worldwide licensing agreement with Merck KGaA, Darmstadt, Germany, for use of PDS Biotechnology's novel Versamune nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in pre-clinical development.

9 Jul 2012

High expression of interleukin-9 in immune cells inhibits melanoma growth

Researchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.

9 Jul 2012

Scientists use antibody injections to rapidly reverse onset of Type I diabetes in mice

Scientists at the University of North Carolina School of Medicine have used injections of antibodies to rapidly reverse the onset of Type I diabetes in mice genetically bred to develop the disease. Moreover, just two injections maintained disease remission indefinitely without harming the immune system.

6 Jul 2012

HIV therapy: Interview with Joël Crouzet, CEO of InnaVirVax

HIV therapy has traditionally been associated with antiretrovirals, which considerably reduce the amount of virus present in the blood to nearly undetectable levels.

29 Jun 2012

Second potential immune checkpoint target for cancer immunotherapy announced by Compugen

Compugen Ltd. (NASDAQ: CGEN) announced today results demonstrating the therapeutic potential of CGEN-15022, a Compugen-discovered B7/CD28-like membrane protein, as an immune checkpoint target for treatment of multiple cancers.

27 Jun 2012

New patent filed for VAC-3S, an immunotherapy for treating HIV infections

InnaVirVax, a biopharmaceutical company specialized in the research and development of therapeutic and diagnostic innovations focused on immune dysregulation, announced today that a new European patent application has been filed on VAC-3S, a “first-in-class” immunotherapy for the treatment of HIV infections.

19 Jun 2012

DBV Technologies’ Viaskin safe and effective in treating children with peanut allergy

DBV Technologies, creator of Viaskin, a new standard in the treatment of allergy, announced today that AP-HP (Assistance Public - Hôpitaux de Paris) sponsor of the ARACHILD study presented at the EAACI Congress a late breaking oral presentation on safety and efficacy data after six months of epicutaneous immunotherapy in peanut allergy using Viaskin Peanut.

18 Jun 2012

Latest allergy research presented at EAACI Congress 2012

Ground-breaking research results about stress during pregnancy and changes in pollen potency across Europe will be presented - among other novel research - at the world's leading congress on allergy and immunology - the EAACI Congress 2012 - that will open tomorrow in Geneva, Switzerland.

16 Jun 2012

Quest receives FDA clearance to initiate oregovomab Phase II trial in ovarian cancer

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has received clearance from the United States Food and Drug Administration to initiate U.S. sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.

15 Jun 2012

Hay fever vaccine shows efficacy in phase IIa trial

A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.

14 Jun 2012

Antibody that blocks programmed cell death benefits cancer patients

A national research collaboration of senior researchers, including a researcher from Moffitt Cancer Center, has found that 20 to 25 percent of "heavily pre-treated" patients with a variety of cancers who enrolled in a clinical trial had "objective and durable" responses to a treatment with BMS-936558, an antibody that specifically blocks programmed cell death 1 (PD-1).

14 Jun 2012

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

14 Jun 2012

Novo Nordisk, JDRF partner to discover and develop novel immunotherapies against T1D

To address the underlying autoimmune process that is central to type 1 diabetes (T1D), JDRF and Novo Nordisk are partnering to discover and develop novel immunotherapies to prevent, treat, and help cure the disease.

14 Jun 2012

New synthetic vaccine effective in killing HPV-derived cancer

Researchers at Moffitt Cancer Center have developed and tested in mice a synthetic vaccine and found it effective in killing human papillomavirus-derived cancer, a virus linked to cervical cancers among others.

10 Jun 2012

Enrollment complete in Advaxis’ ADXS-HPV Phase 2 study on CIN 2/3

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has completed enrollment of 40 patients in the second of three dose cohorts in Lm-LLO-E7-07, a randomized, single blind, placebo controlled Phase 2 dose escalation study assessing the safety and efficacy of ADXS-HPV for the treatment of cervical intraepithelial neoplasia (CIN) 2/3.

7 Jun 2012

New immune response data from Generex’s AE37 Phase II trial on breast cancer

Generex Biotechnology Corporation announced today that new immune response data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine undertaken by Generex wholly-owned subsidiary Antigen Express, Inc. was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2, 2012 in Chicago, IL.

6 Jun 2012

New PD-1 blocking antibody shows promise against advanced kidney cancer

An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center.

5 Jun 2012

Parkinson’s vaccine: worldwide first clinical trial begins

The worldwide first clinical trial for the development of a Parkinson´s vaccine has now been started by AFFiRiS AG.

5 Jun 2012

Jennerex announces data from JX-594 clinical studies on cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer was featured in three separate abstracts during the American Society of Clinical Oncology (ASCO) Annual Meeting currently taking place in Chicago, Illinois.

5 Jun 2012

Immunotherapy News and Research

Latest Immunotherapy News and Research

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

Merck, PDS Biotechnology enter licensing agreement for Versamune

High expression of interleukin-9 in immune cells inhibits melanoma growth

Scientists use antibody injections to rapidly reverse onset of Type I diabetes in mice

HIV therapy: Interview with Joël Crouzet, CEO of InnaVirVax

Second potential immune checkpoint target for cancer immunotherapy announced by Compugen

New patent filed for VAC-3S, an immunotherapy for treating HIV infections

DBV Technologies’ Viaskin safe and effective in treating children with peanut allergy

Latest allergy research presented at EAACI Congress 2012

Quest receives FDA clearance to initiate oregovomab Phase II trial in ovarian cancer

Hay fever vaccine shows efficacy in phase IIa trial

Antibody that blocks programmed cell death benefits cancer patients

Advaxis announces publication of preclinical research with ADXS-PSA

Novo Nordisk, JDRF partner to discover and develop novel immunotherapies against T1D

New synthetic vaccine effective in killing HPV-derived cancer

Enrollment complete in Advaxis’ ADXS-HPV Phase 2 study on CIN 2/3

New immune response data from Generex’s AE37 Phase II trial on breast cancer

New PD-1 blocking antibody shows promise against advanced kidney cancer

Parkinson’s vaccine: worldwide first clinical trial begins

Jennerex announces data from JX-594 clinical studies on cancer

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in